Omega 3 Ethyl Esters
Oral soft-gel capsule (1g per capsule)Available in all 50 statesMarketing purposes only. Actual medications, if prescribed, are dispensed by a licensed pharmacy.
heart · triglyceride management
Pharmaceutical-grade omega-3 ethyl esters (the generic equivalent of Lovaza) deliver concentrated EPA and DHA at therapeutic doses well above what's available in OTC fish oil. Used primarily to lower elevated triglycerides and as an adjunct in cardiometabolic risk reduction. Ultra-purified to pharmaceutical standards, with no detectable mercury.
Significant triglyceride reduction (typically 20 to 45%)
Adjunct in cardiovascular risk-reduction protocols
Pharmaceutical grade, ultra-purified EPA + DHA, no detectable mercury
FDA-approved for severe hypertriglyceridemia (≥500 mg/dL)
No commitment · HSA/FSA eligibleNo commitment · HSA/FSA eligible
How it works
Omega-3 ethyl esters concentrate eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at therapeutic doses. They reduce hepatic synthesis of very-low-density lipoprotein (VLDL) triglycerides and increase fatty-acid β-oxidation, which lowers circulating triglyceride levels.
Beyond lipid effects, EPA/DHA influence membrane fluidity, eicosanoid signaling, and platelet aggregation, mechanisms hypothesized to contribute to the cardiovascular outcome differences seen in trials of high-purity formulations.
EPA and DHA are also the direct precursors to specialized pro-resolving mediators (SPMs), the resolvins, protectins and maresins, which act locally at sites of inflammation or tissue damage to actively switch off the inflammatory response and restore normal cellular function. This makes omega-3s one of the few compounds that help resolve inflammation rather than merely suppress it.
EPA also incorporates directly into atherosclerotic plaque, particularly vulnerable thin-cap plaque, where it improves plaque stability and reduces plaque inflammation and foam-cell formation. In the EVAPORATE trial, high-dose EPA ethyl ester produced regression of low-attenuation (vulnerable) plaque on serial CT angiography versus continued progression on placebo. And the stakes are high: population analyses rank low omega-3 intake among the leading dietary risk factors for preventable death in the United States, the same landmark analysis that put smoking, high blood pressure, and obesity at the top of the overall list.
Every Marek client receives this baseline panel before a provider review. Your provider may add additional biomarkers based on your health history, symptoms, and goals, pulling from 1,000+ available markers. See more biomarkers →
Sex hormones
Adrenals & neurosteroids
Growth hormone / IGF-1
Thyroid hormones
Cardiovascular health
Insulin sensitivity
Liver & pancreas
Kidney function
Comprehensive Metabolic Panel (CMP)
Prostate health
Vitamins & minerals
Iron status
Complete Blood Count (CBC)
Clinical evidence
New England Journal of Medicine (2019)
8,179 statin-treated patients with elevated triglycerides. The high-dose EPA-only formulation was associated with a 25% relative reduction in major adverse cardiovascular events versus placebo.
Read study →New England Journal of Medicine (2018)
15,480 patients with diabetes and no prior CV disease. Omega-3 (1 g/day) showed no significant reduction in serious vascular events versus placebo, informing how Marek's providers individualize use.
Read study →Safety profile
FAQ
Eligibility, dose, and duration are determined by a partnered licensed medical provider based on your complete labs and medical history. A prescription is not guaranteed, your provider may recommend Omega 3 Ethyl Esters, a different therapy, or a non-pharmacologic approach.
Treatments are dependent on licensed clinical prescription. Client costs vary based on individual labs and panel in treatments and services.
